Please assess the completion status of the following clinical trial:

Trial Title: A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written Informed Consent~2. ≥18 years of age~3. Diagnosis of HCC~4. Locally advanced HCC~5. Preserved liver function~6. Eastern Cooperative Oncology Group 0 or 1~Exclusion Criteria:~1. Presence of extra-hepatic spread of disease.~2. Macrovascular invasion of lobar portal vein branches or main portal vein.~3. Candidate for surgical resection, transplantation, or local ablation.~4. Prior intra-arterial embolization, chemotherapy or systemic therapy for HCC.~5. Any contraindication for TACE.~6. Platelet count \<50,000/mm3 or international normalized ratio \>1.5.~7. Previous treatment with anthracycline antibiotics (e.g. Doxorubicin) or sorafenib.~8. Unstable coronary artery disease or recent myocardial infarct (i.e. within 1 year).~9. Known ejection fraction \< 50%.~10. Current infections requiring antibiotic therapy.~11. Suffering from a known bleeding disorder.~12. Renal insufficiency (serum creatinine \> 2 mg/dL).~13. Aspartate aminotransferase and/or alanine transaminase \>5 times upper limit of normal.~14. Presence of advanced liver disease.~15. Any contraindication for doxorubicin administration:~16. Any co-morbid condition or social situation, which has a high likelihood of causing poor compliance with the study protocol or jeopardizes the patient's safety.~17. Patient has another primary tumor, with the exception of conventional basal cell carcinoma, superficial bladder cancer, melanoma in situ, or treated prostate cancer currently without biochemical or radiographic evidence of active disease~18. Participation in a clinical trial of an investigational device or drug within 4 weeks of study entry.~19. Pregnant or breast-feeding patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DEB-TACE (Type: EXPERIMENTAL): ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
- Sorafenib (Type: ACTIVE_COMPARATOR): 200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression

Based on this trial design, predict the completion outcome and termination type (if applicable).